Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Orphan drugs: overcoming HTA barriers to access How can orphan drug manufacturers demonstrate value and improve access to drugs?
Debates & Insight Sponsored Approval and access: overcoming the final hurdle of drug dev... 2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater col
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
